NHS England publicly lists 137 hospital trusts as "live" with Palantir's £330 million federated data platform, and claims a subset are "realising benefits." Freedom of information requests to those trusts tell a different story: 29 of them say the system is not live, not in use, or has no implementation timeline. University Hospitals of North Midlands went further, stating flatly: "FDP is not live. We do not intend to roll it out in the future." The disclosure mechanism matters here. NHS England's headline claim — 117,539 additional operations at trusts using FDP — has already been challenged. The department conceded it could not prove cause and effect between FDP adoption and surgical throughput. The Office for Statistics Regulation investigated and is now escalating the matter through its casework function, a step beyond routine inquiry. The definitional sleight of hand is revealing. NHS England counts trusts as "live" if back-office data infrastructure is in place, even when no clinical applications are running. Torbay and South Devon, for instance, is recorded as live because infrastructure supports "data submission, rather than active operational use of FDP apps." This is the equivalent of counting a building as occupied because the plumbing works. Palantir's response has been political rather than technical. The company hired Labour's former deputy leader Tom Watson as a full-time lobbyist. Watson has been posting videos on X to counter criticism and, along with Palantir's UK chief Louis Mosley, writing directly to critical MPs — counting the number of times those MPs have spoken against the company. Labour MP Clive Lewis described the letters as "very Big Brother." Mosley accused critics of "Palantir Derangement Syndrome." The structural question is whether the NHS is building genuine digital capability or renting a platform it cannot fully evaluate, audit, or exit. Chi Onwurah, chair of the Commons science and technology committee, is calling for the government to activate the 2027 break clause and launch open competition for a UK-based supplier. Both the science and health select committees are now pressing ministers. The contract's defenders cite real numbers — a claimed 14.3% reduction in discharge delays for long-stay patients, 5.6% improvement in cancer diagnosis timelines within 28 days. But these figures arrive without causal verification, from a vendor whose corporate incentives run directly through continued NHS dependence. Marc Farr, chair of the NHS Chief Data and Analytics Officers Network, said benefits must be "reported accurately, transparently and in a way that can be properly verified." What we have is a £330 million procurement where the buyer's own published evidence of success does not survive contact with the institutions it claims to describe. That is not a technology problem. It is an accountability problem.
